In-Vivo Science Inc. is a non-clinical research organization (CRO) that provides in vivo efficacy studies using humanized mice and other disease models. The company provides comprehensive support ranging from breeding animals to data analysis, assisting pharma sector from basic discovery to clinical application.
In-Vivo Science Inc. offers drug efficacy study in mice and rats. They have many models available in oncology, cardiovascular, and inflammatory disorders.
In cardiovascular models, they perform non-invasive cardiac function analyses using MRI. This enables precise and quantitative evaluation of therapeutic candidate compounds. By combining disease models with advanced imaging analysis technology, they ensure high accuracy and reliability throughout their service.
In-Vivo Science Inc. offers humanized mice models with immuno-deficient NOG mice. These mice, reconstituted with human immune cells, are used for preclinical assessment of immunotherapies and other advanced treatments.
The platform supports preclinical testing of immunotherapies such as PD-1 inhibitors and CAR-T cell therapies. Because human immune responses can be reproduced in vivo, these models allow drug efficacy to be verified under similar conditions as clinical patients.
In-Vivo Science Inc. provides many animal models suitable for diverse diseases. They offer end-to-end service throughout the whole processe—from animal housing and administration support through observation and data analysis. All studies are performed in-house, allowing seamless support from model selecting, study designing, in -life study to data delivery.
The company’s advantage is in their broad capability to handle various research areas, including oncology, cardiovascular diseases, and arthritis.
In-Vivo Science Inc. provides many advanced human disease models with NOG mice, which exhibit a high level of immuno-deficiency and are well-suited for transplanting human cells and tissues.
These models can reproduce human diseases such as cancer and immune disorders, allowing both efficacy and safety evaluations.
This model can also be applied to PDX (Patient-Derived Xenograft) study with patient-derived cells and tissues. It provides highly clinically relevant preclinical platform.
Reference: https://www.invivoscience.com/nog_mouse.html
This model—created by transplanting human hepatocytes into severely immuno-deficient TK-NOG mice—reconstructs a functional human liver.
Serum proteins( human albumin and human C3) are synthesized, and hepatic metabolic enzymes (e.g., CYP3A4) are expressed at donor-equivalent levels.
This enables high-precision evaluation of human drug metabolism, pharmacokinetics, and safety (toxicity).
Reference: https://www.invivoscience.com/tk-nog_mouse.html
| Address | 3F, No.44 Kowa Building, 1-2-7 Higashiyama, Meguro-ku, Tokyo, Japan |
|---|---|
| Tel | 044-201-8518 |
| Website | https://www.invivoscience.com/ |
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.